Skip to main content
. 2021 Dec 29;24(6):948–958. doi: 10.1093/europace/euab298

Table 4.

Effectiveness outcomes by infarct location

Inferior infarct (N = 135) Non-inferior infarct (N = 124) Sensitivity: anterior infarct (N = 83)
Ablation (N = 63) Escalated therapy (N = 72) Ablation (N = 69) Escalated therapy (N = 55) Ablation (N = 46) Escalated therapy (N = 37)
Primary composite outcome: all-cause mortality, appropriate ICD shock (>30 days post), VT storm (>30 days post)
Crude events, N (%) 38 (60.3%) 47 (65.3%) 40 (58.0%) 40 (72.7%) 29 (63.0%) 27 (72.9%)
Crude incidence per 100 person-years (95% CI) 37.8 (27.5–51.9) 49.9 (37.5–66.4) 35.9 (26.3–48.9) 54.6 (40.1–74.5) 40.6 (28.2–58.5) 57.5 (39.3–83.6)
aHR (95% CI)a 0.80 (0.50–1.29) 0.48 (0.27–0.86) 0.50 (0.23–1.09)
All-cause mortality
Crude events, N (%) 17 (27.0%) 16 (22.2%) 19 (27.5%) 19 (34.6%) 12 (26.1%) 13 (35.1%)
Crude incidence per 100 person-years (95% CI) 10.2 (6.3–16.4) 9.3 (5.7–15.2) 11.9 (7.6–18.7) 15.5 (9.9–24.3) 10.6 (6.0–18.6) 17.8 (10.3–30.6)
aHR (95% CI)a 0.99 (0.46–2.16) 0.58 (0.26–1.32) 0.84 (0.24–3.01)
Appropriate ICD shock (>30 days post)
Crude events, N (%) 25 (39.7%) 29 (40.3%) 25 (26.2%) 25 (45.5%) 19 (41.3%) 16 (43.2%)
Crude incidence per 100 person-years (95% CI) 22.1 (14.9–32.7) 24.5 (17.0–35.2) 20.0 (13.5–29.5) 30.7 (20.8–45.5) 23.0 (14.7–16.2) 30.7 (18.8–59.1)
aHR (95% CI)a 0.99 (0.53–1.84) 0.55 (0.28–1.09) 0.75 (0.31–1.86)
VT storm (>30 days post)
Crude events, N (%) 19 (35.9%) 21 (29.2%) 15 (21.7%) 19 (34.6%) 12 (26.1%) 7 (18.9%)
Crude incidence per 100 person-years (95% CI) 15.1 (9.6–23.6) 16.6 (10.8–25.5) 11.7 (7.0–19.3) 20.6 (20.8–45.5) 15.3 (8.7–16.9) 10.7 (5.1–22.4)
aHR (95% CI)a 1.30 (0.56–2.86) 0.62 (0.27–1.43) 2.02 (0.59–6.93)

aHR, adjusted hazard ratio; CI, confidence interval; ICD, implantable cardioverter-defibrillator; VT, ventricular tachycardia.

a

HRs were inverse probability of treatment weighted. The variables included in the propensity score for the weights included age, sex, comorbidities, heart rate, type of ICD, number of ICD shocks, and ATP within the 3 months prior to randomization, medications, and the location of additional infarctions.